Nov 12, 2019
Eiger Announces Peginterferon Lambda - Lonafarnib Combination Interim Results in Hepatitis Delta Virus (HDV) Infection from Phase 2 LIFT Study During Late-Breaker Oral Presentation at AASLD 2019
Nov 12, 2019
Global hepatitis test solution/diagnosis market is expected to grow with a CAGR of 4.1% over the forecast period from 2019-2025
Nov 11, 2019
Echosens at VA’s National Veterans Small Business Engagement Meeting: Demonstrating FibroScan Benefits for Early Detection and Monitoring of Liver Disease
Nov 09, 2019
qFIBS Demonstrates Suitability for Nonalcoholic Steatohepatitis (NASH) Assessment in Clinical Trials and Patient Care with Full Quantification of All Crucial Histopathological Features
Nov 07, 2019
NetNoggin® releases exploratory analysis "Healthcare Provider Needs in the NASH Market"
Nov 06, 2019
DURECT to Host Key Opinion Leader Call on DUR-928 Phase 2a Alcoholic Hepatitis Study Results
Nov 04, 2019
DURECT Corporation Announces Third Quarter 2019 Financial Results and Update of Programs
Oct 30, 2019
Galmed Pharmaceuticals to Report Third Quarter 2019 Financial Results and Provide Business Update on Wednesday, November 6
Oct 30, 2019
PharmaNest Announces New Adult and Pediatric NASH Data to Be Presented at the AASLD - Liver Meeting® 2019
Oct 26, 2019
HistoIndex Announces Global Partnerships To Expand AI-Based Digital Pathology Platform As A Drug Discovery Tool In Preclinical Studies For Nonalcoholic Steatohepatitis (NASH)
Oct 23, 2019
Pliant Therapeutics Announces Strategic Collaboration to Develop Novel Therapies for NASH and Fibrotic Diseases
Oct 22, 2019
HighTide Therapeutics Announces Completion of Enrollment in Phase 2a NASH Study of HTD1801
Oct 22, 2019
OrigiMed: The largest cohort study on HBV-Related hepatocellular carcinoma in China released in Cell
Oct 21, 2019
Eiger Announces Peginterferon Lambda Combination Therapy for Treatment of Chronic Hepatitis Delta Virus (HDV) Infection to be Featured in a Late-Breaking Oral Presentation at AASLD 2019
Oct 21, 2019
DURECT Announces DUR-928 Phase 2a Alcoholic Hepatitis Study Results Selected for Late-Breaking Oral Presentation at The Liver Meeting® 2019
Oct 21, 2019
B. Riley FBR to Host NASH Symposium in San Francisco on October 24, 2019
Oct 16, 2019
Hepagene Therapeutics, Inc, Announces Dosing of First Healthy Subject in a Phase I Study of HPG1860 for NASH
Oct 10, 2019
Data to be Presented at AASLD 2019 Shows HighTide Lead Compound Improves NASH in Two Animal Models
Oct 08, 2019
Clinicians Not Consistent With Guidelines When Managing HIV/HCV Coinfection
Oct 03, 2019
Akero Therapeutics and InSphero partner to evaluate AKR-001 using InSphero's 3D InSight(TM) Human Liver Disease platform